TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01208701
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zarator, 80 mg pr day for 5 days
Study: NCT03381495
Drug: Ropivacaine Hydrochloride, Sufentanil
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this research one group will receive epidural analgesia(Ropivacaine Hydrochloride, Sufentanil), data will be collected and analyzed between this group and non-epidural analgesia group.
Study: NCT00002803
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03036163
Drug: PBTZ169 - 320 mg (multiple administration)
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days
Study: NCT03036163
Drug: PBTZ169 - 640 mg (multiple administration)
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days
Study: NCT03543254
Drug: BoNT-A
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90U BoNT-A, given in one treatment as 18 injections of 5u (0.2 ml) each, on specific preselected sites along the sutures of the skull.~First 100 U of Botox® is solved in 4 ml (cc) of isotone saline water (9 mg/ml), distributed in 4 syringes. This is half the usual concentration, allowing for better diffusion in order to reach the target structures.
Study: NCT02048228
Drug: genotyping guided therapy Ticagrelor, Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CYP2C19\*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.
Study: NCT02048228
Drug: standard therapy clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
Study: NCT00386984
Drug: Somatostatin (octreotide)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00504751
Drug: bortezomib, dexamethasone, ifosfamide
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5
Study: NCT00504751
Drug: mesna, cisplatin, etoposide, rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5
Study: NCT02054338
Drug: Vinflunine+Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vinflunine 320 mg/m² IV on day 1 and.Gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks
Study: NCT02054338
Drug: Paclitaxel+Gemcitabine
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1
Study: NCT03222310
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 100 mg tablet orally once daily.
Study: NCT03222310
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 100 mg capsules orally once daily.
Study: NCT00072267
Drug: 7-hydroxystaurosporine
Normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00072267
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00796081
Drug: ER OROS paliperidone, paliperidone ER
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01283412
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 0.1\~0.2ug/kg/h iv. during the operation, and stoped 30min before end of surgery
Study: NCT01952626
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT01952626
Drug: Palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous injection
Study: NCT04337814
Drug: EMLA Cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anaesthetic cream
Study: NCT00707031
Drug: Lixisenatide (AVE0010)
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study: NCT00707031
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.
Study: NCT00707031
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study: NCT00182754
Drug: octreotide acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given subcutaneously
Study: NCT00234065
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years
Study: NCT00234065
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years
Study: NCT03584698
Drug: Misoprostol 100Mcg Tab
Normalized name: MISOPROSTOL 100MCG TAB
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.
Study: NCT03584698
Drug: Evening Primrose Oil 1000 MG
Normalized name: evening primrose oil 1000 MG
DrugBank: Evening primrose oil (DB11358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.
Study: NCT02932462
Drug: DSXS
Normalized name: Dexamethasone sodium succinate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical product
Study: NCT00652340
Drug: apricoxib/erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: apricoxib: 100 mg tablets, 400mg/day~erlotinib: per package insert
Study: NCT00652340
Drug: erlotinib/placebo
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: erlotinib: per package insert~placebo: 100 mg tablets, 400 mg/day
Study: NCT04258592
Drug: (18F)MFBG
Normalized name: Fludeoxyglucose (18F)
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One intravenous injection of 4 MBq/kg (adults) One intravenous injection of 2 MBq/kg (minor participants)
Study: NCT00578474
Drug: Ofloxacin otic solution
Normalized name: ofloxacin Otic Solution
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 drops into the infected ear(s) twice daily (morning and evening) for 10 days
Study: NCT04261790
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be treated with two courses of ocrelizumab (Ocrevus) 600mg/course, for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
Study: NCT01494259
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to 300cc of 0.5% bupivacaine administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
Study: NCT01494259
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to 300cc of normal saline administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
Study: NCT04493671
Drug: TBAJ-876 10mg
Normalized name: TBAJ-876
DrugBank: TBAJ-876 (DB18807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBAJ-876 10mg tablets, oral suspension, orally administered
Study: NCT04493671
Drug: TBAJ-876 25mg
Normalized name: TBAJ-876
DrugBank: TBAJ-876 (DB18807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBAJ-876 25mg tablets,oral suspension, orally administered
Study: NCT04493671
Drug: TBAJ-876 50mg
Normalized name: TBAJ-876
DrugBank: TBAJ-876 (DB18807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBAJ-876 50mg tablets,oral suspension, orally administered
Study: NCT04493671
Drug: TBAJ-876 100mg
Normalized name: TBAJ-876
DrugBank: TBAJ-876 (DB18807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBAJ-876 100mg tablets, oral suspension, orally administered
Study: NCT04493671
Drug: TBAJ-876 200mg
Normalized name: TBAJ-876
DrugBank: TBAJ-876 (DB18807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBAJ-876 200mg tablets, oral suspension, orally administered
Study: NCT04493671
Drug: TBAJ-876 400mg
Normalized name: TBAJ-876
DrugBank: TBAJ-876 (DB18807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBAJ-876 400mg tablets, oral suspension, orally administered
Study: NCT04493671
Drug: TBAJ-876 Dose XXXmg for Food cohort
Normalized name: TBAJ-876
DrugBank: TBAJ-876 (DB18807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on exposure levels from initial cohorts, a dose will be chosen for the food-effect cohort.
Study: NCT04493671
Drug: TBAJ-876 XXXmg for Part 2
Normalized name: Echinacea, aerial parts
DrugBank: TBAJ-876 (DB18807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2, Multiple ascending dose (MAD) cohorts doses to be determined.
Study: NCT04493671
Drug: Matching Placebo for TBAJ-876 tablet
Normalized name: TBAJ-876
DrugBank: TBAJ-876 (DB18807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered
Study: NCT01004809
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT02603016
Drug: GLSE compound
Normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02603016
Drug: Ginseng compound
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01019434
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
Study: NCT01019434
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
Study: NCT03593837
Drug: Huang qi gui zhi wu wu granule
Normalized name: Ci Wu Jia
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
Study: NCT03593837
Drug: Huang qi gui zhi wu wu granule placebo
Normalized name: Ci Wu Jia
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
Study: NCT01895777
Drug: dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
Study: NCT00309855
Drug: Anastrazole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally x 21 days
Study: NCT00309855
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally x 21 days
Study: NCT00645892
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
Study: NCT00645892
Drug: placebo for adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
Study: NCT02224157
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
Study: NCT02224157
Drug: budesonode bid + terbutaline 'as needed'
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
Study: NCT01975077
Drug: fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily
Study: NCT00223691
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
Study: NCT00223691
Drug: Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25-100 mg, PO. Single dose.
Study: NCT00223691
Drug: Pyridostigmine Bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
Study: NCT00223691
Drug: Yohimbine
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
Study: NCT00223691
Drug: Midodrine HCl
Normalized name: midodrine HCl
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5, 5.0, 7.5, 10 mg PO. Single dose
Study: NCT00223691
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50-400 mg PO. Single dose
Study: NCT00223691
Drug: Octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-50 µg, S.C. Single dose.
Study: NCT00223691
Drug: Diphenhydramine Hydrochloride
Normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
Study: NCT00223691
Drug: Ranitidine HCL
Normalized name: ranitidine HCl
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
Study: NCT00223691
Drug: Tranylcypromine
Normalized name: Tranylcypromine
DrugBank: Tranylcypromine (DB00752)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 - 40 mg PO. Single dose
Study: NCT00223691
Drug: Pseudoephedrine
Normalized name: Pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15, 30 or 60 mg, PO. Single dose.
Study: NCT00223691
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 or 10 mg PO. Single dose.
Study: NCT00223691
Drug: Oxymetazoline 0.05% nasal solution
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-2 sprays/ nostril. Single dose.
Study: NCT00223691
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
Study: NCT00223691
Drug: Rivastigmine tartrate
Normalized name: Rivastigmine Tartrate
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.5-6 mg PO. Single dose.
Study: NCT01480479
Drug: Rindopepimut (CDX-110) with GM-CSF
Normalized name: sipuleucel-T
DrugBank: Rindopepimut (DB05374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.~Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
Study: NCT01480479
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
Study: NCT01480479
Drug: KLH
Normalized name: KLH
DrugBank: Keyhole limpet hemocyanin (DB05299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
Study: NCT00371111
Drug: Intravitreal injection of Triamcinolone
Normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg of Triamcinolone
Study: NCT01198132
Drug: Rebif
Normalized name: Rebif
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
Study: NCT00175604
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: The babies that require a neck collar for CMT will be randomly placed into two groups. One group will receive standard treatment which includes physiotherapy and occupational therapy. The other group will receive standard treatment plus an injection of Botox.
Study: NCT01625897
Drug: MP-214
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214
Study: NCT01625897
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone
Study: NCT03598257
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03372629
Drug: ID-085
Normalized name: menthol 0.085 MG/MG
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg
Study: NCT03536598
Drug: Amlodipine 10 mg + Valsartan 160 mg
Normalized name: amlodipine / valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02021825
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
Study: NCT00234819
Drug: Bazedoxifene/Conjugated Estrogen
DrugBank: Bazedoxifene (DB06401)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03424577
Drug: H3B-6527
Normalized name: H3B-6527
DrugBank: H3B-6527 (DB15169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT03393468
Drug: Dapivirine gel
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine gel (0.05%); administered rectally
Study: NCT02776956
Drug: atorvastatin group
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in atorvastatin group will orally receive 20 mg of atorvastatin per night (Pfizer) for three days before the operation and three months after the operation
Study: NCT02776956
Drug: non-atorvastatin group
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in non-atorvastatin group will not receive atorvastatin before the operation and after the operation.
Study: NCT00156065
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-8 mg BID
Study: NCT00156065
Drug: Asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 or 10 mg BID
Study: NCT02494778
Drug: Pridopidine
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg BID
Study: NCT01059396
Drug: propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GPVH ≥ 10 mmHg - responders: propranolol.
Study: NCT01059396
Drug: carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GPVH ≥ 10 mmHg nonresponders: carvedilol.